We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




RFA Destroys Kidney Cancers and Deters Recurrence

By HospiMedica staff writers
Posted on 20 Feb 2003
A study has shown that radiofrequency ablation (RFA) destroyed all renal cell carcinoma tumors in 34 patients, of whom 32 have had no local recurrence during the follow-up period. More...
The results were reported in the February 2003 issue of Radiology.

Renal cell carcinoma is the most common form of kidney cancer and is most often treated with surgical removal. Researchers at several medical centers have used RFA for patients for whom surgery was not an option. The current study reports on what may be the largest number of such patients treated and the longest follow-up time. RFA delivers heat generated by electrical energy to tumor sites through a thin needle, with placement guided by ultrasound or other imaging technique.

A total of 42 individual tumors were treated in the new study, ranging in size from 1-9 cm. All tumors located on the surface of the kidney were completely destroyed, regardless of size. While larger tumors within the central kidney were more difficult to treat, more than half of those treated were destroyed with additional treatments. Follow-up ranged from three months to three-and-a-half years. Four patients died of unrelated causes, two of whom had no tumor recurrence. The other 30 patients have had no local recurrence. None of the patients with limited kidney function needed to have dialysis.

"I am optimistic that, with further study, RFA will someday become the standard of care for selected kidney tumors,” said W. Scott McDougal, M.D., a co-author and chief of urology at Massachusetts General Hospital (Boston, USA).




Related Links:
Massachusetts General Hospital

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.